El neuroblastoma es el tumor extracraneal sólido más frecuente en la infancia. Su comportamiento es muy heterogéneo, pudiéndose dar desde regresión espontánea hasta tumores metastásicos muy agresivos. Uno de los factores pronóstico más usados es la amplificación del oncogén MYCN, que es indicativo de baja supervivencia. Aunque, dada la baja...
-
February 10, 2020 (v1)PublicationUploaded on: December 4, 2022
-
May 16, 2022 (v1)Publication
No description
Uploaded on: March 25, 2023 -
April 22, 2020 (v1)Publication
No description
Uploaded on: March 25, 2023 -
November 11, 2019 (v1)Publication
BACKGROUND: Neuroblastoma is a paediatric tumour originated from sympathoadrenal precursors and characterized by its heterogeneity and poor outcome in advanced stages. Intra-tumoral cellular heterogeneity has emerged as an important feature in neuroblastoma, with a potential major impact on tumour aggressiveness and response to therapy. CD44 is...
Uploaded on: March 26, 2023 -
October 19, 2021 (v1)PublicationIdentification of vrk1 as a new neuroblastoma tumor progression marker regulating cell proliferation
Neuroblastoma (NB) is one of the most common pediatric cancers and presents a poor survival rate in affected children. Current pretreatment risk assessment relies on a few known molecular parameters, like the amplification of the oncogene MYCN. However, a better molecular knowledge about the aggressive progression of the disease is needed to...
Uploaded on: March 25, 2023